General Information of Drug (ID: DM32YTJ)

Drug Name
APN-301 Drug Info
Synonyms EMD-273063; Ch14.18-IL-2; Hu14.18-IL-2
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Neuroblastoma 2D11.2 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM32YTJ

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-2 (IL2) TTF89GD IL2_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-2 (IL2) DTT IL2 0.848 4.548 3.548 4.053
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-2 (IL2) DTT IL2 7.64E-01 1.04E-02 0.07
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00590824) Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of APEIRON Biologics.